Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTPYS82)

• DTT Name: Interleukin 3 receptor (CSF2RB) DTT Info
• Gene Name: CSF2RB

Molecule-Related Drug & Molecule List

5 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Leridistim	DM6DL5K	Immune System disease	4A01-4B41	Phase 2	[1]
TPI ASM8	DMAWLVB	Asthma	CA23	Phase 2	[2]
DT388IL-3	DMRXQCL	Acute myeloid leukaemia	2A60	Phase 1/2	[3]
SL-401	DMOCHVE	Acute myeloid leukaemia	2A60	Phase 1/2	[4]
CSL-362	DMO97RV	Acute myeloid leukaemia	2A60	Phase 1	[5]

References

• [1] Leridistim, a chimeric dual G-CSF and IL-3 receptor agonist, enhances multilineage hematopoietic recovery in a nonhuman primate model of radiation-induced myelosuppression: effect of schedule, dose, and route of administration. Stem Cells. 2001;19(6):522-33.
• [2] Target mRNA inhibition by oligonucleotide drugs in man. Nucleic Acids Res.2012 Nov;40(21):10585-95.
• [3] Safety evaluation of DT388IL3, a diphtheria toxin/interleukin 3 fusion protein, in the cynomolgus monkey. Cancer Immunol Immunother. 2005 Aug;54(8):799-806.
• [4] Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood. 2014 Jul 17;124(3):385-92.
• [5] Monoclonal antibody targeting of IL-3 receptor alpha with CSL362 effectively depletes CML progenitor and stem cells. Blood. 2014 Feb 20;123(8):1218-28.